Hemophilia: Triumphs, Challenges, and Shared Decision Making in the Management of Hemophilia A (Specialty Centers)
This activity contains:
- CME/CPE/CNE/NASW-Certified Live Grand Rounds
- Shared Decision Making Facilitation Guide (non-certified resource; scheduled release date of November 2017)
- Downloadable Slide Deck with Facilitator’s Guide for Hemophilia Treatment Centers (non-certified resource; scheduled release date of January 2018)
The goal of this activity is to translate emerging evidence for treating hemophilia A into actual clinical practice to improve patient outcomes.
Hemophilia A is a rare bleeding disorder caused by deficiency of clotting factor VIII. The current standard of care for patients with severe hemophilia A centers on replacement therapy with factor VIII concentrate, either on demand when bleeding occurs or prophylactically (replacement therapy). Potential complications from replacement therapy include the development of inhibitory antibodies that attack the clotting factor in approximately one-fourth of patients, viral infections from human clotting factors, and bleeding in joints and muscles resulting from treatment delays. According to treatment guidelines from the Medical and Scientific Advisory Council (MASAC), “Inhibitor development is the most severe complication of treatment for patients with inherited hemophilia A.” In addition, the high cost and frequency of infusing factor VIII concentrates can increase the potential for side effects, thereby negatively affecting patient quality of life.
Fortunately, several unique agents have been newly approved or are currently under development. These agents promise to reduce morbidity and improve quality of life for patients. Better prophylactic alternatives are needed, and as the science of hemophilia care evolves, clinicians will be challenged to integrate these new agents into their clinical practices.
This activity will review current and novel approaches to treating hemophilia A, treatment for inhibitor development, and shared decision-making approaches to treatment so that the interprofessional healthcare team engaged in treating hemophilia A can translate emerging evidence into actual clinical practice and effectively manage hemophilia A.
- Activity Overview
- Current and Novel Approaches to Treating Hemophilia A
- Understanding Screening and Treatment Options for Inhibitor Development
- Implementing a Shared Decision-Making Approach
- Case Challenges
- Activity Conclusion and Q&A
This activity is intended for hemophilia treatment center hematologists, hemophilia specialists, nurses, fellows, pharmacists, social workers, orthopedic, pediatric, lab, and other allied healthcare professionals as part of the interdisciplinary care team involved with optimizing patient outcomes in hemophilia A management.
At the conclusion of this activity, participants should be better able to:
- Apply the latest safety and efficacy data for newly approved and emerging agents in clinical decision making for the treatment of hemophilia A
- Devise strategies for testing and monitoring of inhibitors, based on current guideline recommendations
- Develop evidence based treatment plans for patients with factor VIII inhibitors
- Develop approaches for implementing shared decision making between clinicians and patients
Craig M. Kessler, MD
Eric H. Kraut, MD
Cindy Leissinger, MD
|Charles Nakar, MD|
Indiana Hemophilia and Thrombosis Center
|Doris Quon, MD, PhD|
Medical Director, Orthopedic Hemophilia Treatment Center
Orthopedic Institute for Children
Los Angeles, CA
|Amy D. Shapiro, MD|
Medical Director, Indiana Hemophilia and Thrombosis Center
|Christopher Walsh, MD, PhD |
Associate Professor, Icahn School of Medicine at Mount Sinai
New York, NY
|Guy Young, MD|
Director, Hemostasis and Thrombosis Center, Children’s Hospital Los Angeles
Professor of Pediatrics, University of Southern California Keck School of Medicine
Los Angeles, CA
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Credit Designation for Physicians
AXIS Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit Designation for Pharmacists
This application-based activity is approved for 1.0 contact hours of continuing pharmacy education credit (0592-0000-17-042-L01-P).
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 1.0 contact hour.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
California Board of Registered Nursing
AXIS is approved by the California Board of Registered Nursing, Provider Number 16702, for 1.0 contact hour.
Iowa Board of Nursing
AXIS is Iowa Board of Nursing approved provider number 371. This program is awarded 1.0 contact hour.
This program is Approved by the National Association of Social Workers (Approval # 886749394-2183) for 1.0 continuing education contact hours.
This NASW approval is not accepted in the states of Idaho, Michigan, New Jersey, New York, Oregon, and West Virginia.
AXIS Contact Information
For information about the certification of this activity, please contact AXIS at email@example.com
Disclosure of Conflicts of Interest
AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
|Name of Faculty or Presenter||Reported Financial Relationship|
|Craig M. Kessler, MD||Craig M. Kessler, MD, reported a financial interest/relationship or affiliation in the form of Advisor/consultant/receives income for consultancy for Bayer Healthcare, Inc.; Biogen IDEC Inc.; Genentech, Inc.; Novo Nordisk; Octapharma Plasma; Pfizer, Inc.; Shire; Research/grant, Bayer Healthcare, Inc.; Genentech, Inc.; Novo Nordisk; Shire|
|Eric H. Kraut, MD||Eric H. Kraut, MD, reported a financial interest/relationship or affiliation in the form of Safety monitoring board, Dimensions Therapeutics, Inc.|
|Cindy Leissinger, MD||Cindy Leissinger, MD, reported a financial interest/relationship or affiliation in the form of Advisory board, Bayer Healthcare, Inc.; Biogen IDEC Inc.; CSL Behring; Kedrion Biopharma; Novo Nordisk; Octapharma Plasma; Roche; Shire; Research grant, CSL Behring; Roche; Shire|
|Charles Nakar, MD||No real or apparent conflicts of interest to report.|
Doris Quon, MD, PhD
|Doris Quon, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant, Baxlata/Shire; Bayer Healthcare, Inc.; CSL Behring; Grifols; Genentech, Inc.; Novo Nordisk; Pfizer, Inc.; Serve(d) as a member of a speakers bureau for Baxalta/Shire; Bioverativ; Grifols; Novo Nordisk; Pfizer, Inc.|
|Amy D. Shapiro, MD||No real or apparent conflicts of interest to report.|
|Christopher Walsh, MD, PhD||Christopher Walsh, MD, PhD, reported a financial interest/relationship or affiliation in the form of Consultant Alynylam Pharmaceuticals; Bioverativ; Catalyst Pharmaceuticals; CSL Behring; Genentech, Inc.; Novo Nordisk; Octapharma Plasma; Shire; Serve(d) as a member of a speakers bureau for Novo Nordisk|
|Guy Young, MD||Guy Young, MD, Guy Young, MD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a member of a speakers bureau for Bioverativ; CSL Behring; Genentech, Inc.; Grifols; Novo Nordisk; Roche; Shire; Received income in any amount from Kedrion Biopharma|
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: The following AXIS planners and managers, Linda Gracie-King, MS; Jocelyn Timko, BS; Thalia Gray; and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars. Robert Mocharnuk, MD, reports a financial interest/relationship or affiliation in the form of Common stock: Merck.
This activity is supported by an educational grant from Genentech.
There is no fee for this educational activity.
This activity is provided by:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Attendance